Business
HLS Therapeutics announces Health Canada grants medical device license for White Blood Cell Point-of-Care Device to be marketed as CSAN® PRONTO(TM)
HLS Therapeutics announces Health Canada grants medical device license for White Blood Cel...
About this update from Hls Therapeutics, Inc.
[{"type":"text","content":"\n\n\n\nHLS Therapeutics announces Health Canada grants medical device license for White Blood Cell Point-of-Care Device to be marketed as CSAN® PRONTO™\n\n/* Style Definitions */\nspan.prnews_span\n{\nfont-size:8pt;\nfont-family:\"Arial\";\ncolor:black;\n}\na.prnews_a\n{\ncolor:blue;\n}\nli.prnews_li\n{\nfont-size:8pt;\nfont-family:\"Arial\";\ncolor:black;\n}\np.prnews_p\n{\nfont-size:0.62em;\nfont-family:\"Arial\";\ncolor:black;\nmargin:0in;\n}\n.prngen2{\nBORDER-TOP:black 0pt; BORDER-RIGHT:black 0pt; VERTICAL-ALIGN: TOP; BORDER-BOTTOM:black 0pt; TEXT-ALIGN: LEFT; PADDING-LEFT:0.50em; BORDER-LEFT:black 0pt; PADDING-RIGHT:0.50em\n}\n.prnsbt0{\nBORDER-TOP:0pt\n}\n.prnsbr0{\nBORDER-RIGHT:0pt\n}\n.prnbcc{\nBORDER-COLLAPSE: COLLAPSE\n}\n.prnsbl0{\nBORDER-LEFT:0pt\n}\n.prnsbb0{\nBORDER-BOTTOM:0pt\n}\n\n\n\n\n\n\n\nCanada NewsWire\nTORONTO, Oct. 17, 2019\n\n\n\nFrom a single drop of blood from the tip of a finger, Athelas One WBC System generates white blood cell counts and neutrophils percentages in minutesThe device could help lower the most commonly cited barrier for using Clozaril® among those who could benefit from itHLS has the exclusive Canadian rights to the device in the field of schizophrenia under a licensing agreement with Athelas, Inc. (\"Athelas\")The device will become part of the Clozaril Support and Assistance Network (CSAN®) and made available to Canadian Institutions and HCPs under the name CSAN® Pronto™ TORONTO, Oct. 17, 2019 /CNW/ - HLS Therapeutics Inc. (\"HLS\" or the \"Company\") (TSX:HLS), a specialty pharmaceutical company focusing on central nervous system and cardiovascular markets, announces that Health Canada has granted a medical device license for the Athelas One WBC System for use as a point-of-care device indicated for quantitative determination of white blood cells (WBC) and neutrophil percentages in capillary or venous whole blood. This medical device may help enhance and simplify the mandatory safety blood monitoring process for Treatment Resistant Schizophrenia (\"TRS\") patients that are prescribed Clozaril® (clozapine). HLS intends to launch the device as part of its current Clozaril Support and Assistance Network (\"CSAN®\") program under the name, CSAN® Pronto™.\n\"Clozapine has provided effective treatment for TRS patients for more than...